Orchard Therapeutics (NASDAQ: ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy® (atidarsagene autotemcel) has been accepted for evaluation by the Swiss Agency for Therapeutic Products (Swissmedic) for the potential treatment of eligible patients with early-on
An investigation by the UK's Health Security Agency (UKHSA) found the Immensa laboratory to have misreported around 39,000 tests as negative when they should have been positive between September 2 and October 12, 2021.